October 28, 2025

Head and Neck Study Presented by Robert Haddad, MD 

Dana-Farber's Dr. Robert Haddad says research shows the combination of a PD1 with anti-LAG3 +/- anti-TIM3 does not improve outcomes in metastatic disease, raising the question of whether to look at this combo earlier, in the neoadjuvant setting.

Dana-Farber

October 22, 2025

Biomarker-Driven Apalutamide Therapy for Patients With Recurrent Prostate Cancer

Use of PAM50 subtyping allowed clinicians to determine which patients with recurrent prostate cancer were most likely to benefit from the addition of apalutamide hormonal therapy to salvage radiothera...

The ASCO Post

October 21, 2025

Localized PI3K-Altered Colorectal Cancer: Does Low-Dose Aspirin Reduce the Risk of Recurrence?

In a Scandinavian trial (ALASCCA) reported in the New England Journal of Medicine, Martling et al found that low-dose aspirin reduced the risk of disease recurrence vs placebo in patients with PI3K-al...

The ASCO Post

October 20, 2025

Updated ASTRO-ASCO-SSO PMRT Guideline: Key Changes and Clinical Implications

New joint clinical practice guidelines from ASTRO, ASCO, and SSO, published in the Journal of Clinical Oncology, provide the most comprehensive update in a decade on postmastectomy radiation therapy (PMRT) for breast cancer.

Baptist Health South Florida

October 20, 2025

Blood Test Guides Post-Surgical Immunotherapy for Muscle-Invasive Bladder Cancer

The Dana-Farber-co-led phase 3 IMvigor011 trial results show that periodic ctDNA screening after surgery can help guide a decision to begin adjuvant immunotherapy.

Dana-Farber

October 14, 2025

Roswell Park Offers Exclusive CAR T-Cell Clinical Trial for Patients with Advanced or Metastatic Hepatoma

 A new, first-in-humans clinical trial for hepatocellular carcinoma uses an “armored” CAR T-cell therapy designed to resist the hostile tumor microenvironment found in 77% of patients with this disease.

Roswell Park Comprehensive Cancer Center

October 14, 2025

FDA Approves Combination Regimen for Extensive-Stage SCLC

Lurbinectedin (Zepzelca) in combination with atezolizumab (Tecentriq) or atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza) was approved for maintenance treatment of adults with extensive-stage s...

The ASCO Post

October 14, 2025

Surgical Resection With EGFR TKI Demonstrates Promising PFS in EGFR-Mutant NSCLC

Resection of the primary thoracic tumor after EGFR tyrosine kinase inhibition demonstrated the ability to prolong disease control in patients with EGFR-mutant metastatic non–small cell lung cancer (NS...

The ASCO Post

October 10, 2025

Prior Authorization Is Burdensome for Patients, Resulting in Treatment Delays, Financial Strain, and Stress

“This study makes clear what many of us in oncology have suspected: Prior authorization isn’t just an administrative hurdle for clinicians; it’s a hidden second job for patients,” noted investigators....

The ASCO Post